Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | INSR | P06213 | 1/20 | 0.69 |
| ▸ | IGF1R | P08069 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.69 |
| ▸ | TNK2 | Q07912 | 15/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.61 |
| ▸ | PRKDC | P78527 | 1/20 | 0.61 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.61 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.61 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.61 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8179182 | 0.93 | RAF1 (0.81) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL593448 | 0.92 | RAF1 (0.82) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL593586 | 0.91 | RAF1 (0.79) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL6942535 | 0.90 | RAF1 (0.74) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL14536972 | 0.90 | RAF1 (0.79) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL593891 | 0.90 | RAF1 (0.76) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL594970 | 0.90 | RAF1 (0.79) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL595908 | 0.90 | RAF1 (1.00) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL593994 | 0.89 | PIK3CA (0.76) | RAF1SRCPDPK1ABL1EGFR | |
| SCHEMBL593992 | 0.89 | PIK3CA (0.76) | RAF1SRCPDPK1ABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | RAF1 260/4885SRC 294/4885PDPK1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.